HC Wainwright Estimates Zymeworks’ Q3 Earnings (NYSE:ZYME)

Zymeworks Inc. (NYSE:ZYME) – Analysts at HC Wainwright issued their Q3 2025 earnings per share estimates for Zymeworks in a report released on Tuesday, October 14th. HC Wainwright analyst R. Burns anticipates that the company will post earnings of ($0.48) per share for the quarter. HC Wainwright has a “Buy” rating and a $26.00 price objective on the stock. The consensus estimate for Zymeworks’ current full-year earnings is ($1.39) per share. HC Wainwright also issued estimates for Zymeworks’ Q4 2025 earnings at ($0.51) EPS, FY2025 earnings at ($1.26) EPS, Q1 2026 earnings at ($0.48) EPS, Q2 2026 earnings at ($0.48) EPS, Q3 2026 earnings at ($0.52) EPS, Q4 2026 earnings at ($0.55) EPS and FY2026 earnings at ($2.02) EPS.

Zymeworks (NYSE:ZYME) last announced its quarterly earnings results on Thursday, August 7th. The company reported $0.03 EPS for the quarter, beating the consensus estimate of ($0.52) by $0.55. Zymeworks had a negative return on equity of 23.00% and a negative net margin of 182.75%.The business had revenue of $48.73 million for the quarter, compared to analyst estimates of $17.18 million. During the same quarter in the prior year, the company posted ($0.49) EPS. The company’s quarterly revenue was up 153.2% on a year-over-year basis.

Several other equities analysts have also issued reports on ZYME. JPMorgan Chase & Co. increased their target price on Zymeworks from $20.00 to $23.00 and gave the stock an “overweight” rating in a research note on Thursday. B. Riley started coverage on Zymeworks in a research note on Friday, October 10th. They set a “buy” rating and a $30.00 target price on the stock. Finally, Citigroup increased their target price on Zymeworks from $19.00 to $22.00 and gave the stock a “buy” rating in a research note on Monday, August 11th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat, Zymeworks currently has an average rating of “Buy” and a consensus target price of $24.75.

Zymeworks Trading Down 0.4%

ZYME opened at $18.55 on Thursday. The stock’s 50-day moving average price is $15.63 and its 200 day moving average price is $13.43. Zymeworks has a 12-month low of $9.03 and a 12-month high of $19.50. The firm has a market cap of $1.39 billion, a price-to-earnings ratio of -12.37 and a beta of 1.51.

Institutional Investors Weigh In On Zymeworks

Large investors have recently bought and sold shares of the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in Zymeworks by 184.2% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 3,879,945 shares of the company’s stock worth $46,210,000 after purchasing an additional 2,514,834 shares during the period. Janney Montgomery Scott LLC increased its holdings in Zymeworks by 12.7% during the 1st quarter. Janney Montgomery Scott LLC now owns 11,567 shares of the company’s stock worth $138,000 after purchasing an additional 1,300 shares during the period. Nuveen LLC purchased a new stake in Zymeworks during the 1st quarter worth about $2,368,000. EcoR1 Capital LLC increased its holdings in Zymeworks by 14.8% during the 1st quarter. EcoR1 Capital LLC now owns 17,259,548 shares of the company’s stock worth $205,561,000 after purchasing an additional 2,231,469 shares during the period. Finally, Vestal Point Capital LP increased its holdings in Zymeworks by 170.3% during the 1st quarter. Vestal Point Capital LP now owns 500,000 shares of the company’s stock worth $5,955,000 after purchasing an additional 315,000 shares during the period. Hedge funds and other institutional investors own 92.89% of the company’s stock.

Zymeworks Company Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.